{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:35Z","timestamp":1787962295132,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1999,5]]},"DOI":"10.1136\/ard.58.5.288","type":"journal-article","created":{"date-parts":[[2008,12,6]],"date-time":"2008-12-06T00:32:33Z","timestamp":1228523553000},"page":"288-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years"],"prefix":"10.1016","volume":"58","author":[{"given":"Margaret-Mary","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan R","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary A","family":"Capell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.58.5.288_bib1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJM198806023182209","article-title":"Drug-related lupus","volume":"318","author":"Hess","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.5.288_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0002-9343(88)90279-3","article-title":"Sulfasalazine-induced lupus erythematosus","volume":"84","author":"Clementz","year":"1988","journal-title":"Am J Med"},{"key":"10.1136\/ard.58.5.288_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/rheumatology\/34.5.435","article-title":"Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease","volume":"34","author":"Laversuch","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib4","first-page":"750","article-title":"Sulphasalazine-induced lupus in rheumatoid arthritis","volume":"21","author":"Caulier","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib5","first-page":"614","article-title":"Sulfasalazine-induced lupus syndrome in a patient with Crohn\u2019s disease","volume":"77","author":"Carr-Locke","year":"1983","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.58.5.288_bib6","first-page":"188","article-title":"Sulphasalazine-induced lupus syndrome in ulcerative colitis","volume":"2","author":"Griffiths","year":"1997","journal-title":"BMJ"},{"key":"10.1136\/ard.58.5.288_bib7","first-page":"85","article-title":"Sulphasalazine-induced lupus like syndrome with cardiac tamponade in a patient with ulcerative colitis","volume":"84","author":"Deboever","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.58.5.288_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/34.4.383","article-title":"Sulphasalazine-induced lupus in a patient with psoriatic arthritis","volume":"34","author":"Veale","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.46.5.408","article-title":"Antibodies to the five histones and poly (adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis","volume":"46","author":"Hobbs","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.58.5.288_bib10","first-page":"496","article-title":"Medication-induced systemic lupus erythematosus","volume":"14","author":"Skaer","year":"1992","journal-title":"Clin Ther"},{"key":"10.1136\/ard.58.5.288_bib11","first-page":"657","article-title":"Drug induced systemic lupus erythematosus","volume":"4","author":"Stratton","year":"1985","journal-title":"Clinical Pharmacy"},{"key":"10.1136\/ard.58.5.288_bib12","first-page":"1887","article-title":"Sulfasalazine has a better efficacy\/ toxicity profile than auranofin: evidence from a 5 year prospective, randomized trial","volume":"23","author":"Mc Entegert","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/ard.53.12.812","article-title":"Outcome of second line therapy in rheumatoid arthritis","volume":"53","author":"Porter","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.58.5.288_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-63-1-100","article-title":"Anti nuclear factors in systemic lupus erythematosus and rheumatoid arthritis","volume":"63","author":"Barnett","year":"1965","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.58.5.288_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780210606","article-title":"A controlled study of ANA+ and RF- arthritis","volume":"21","author":"Linn","year":"1978","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.5.288_bib16","first-page":"750","article-title":"Sulfasalazine induced lupus in rheumatoid arthritis","volume":"21","author":"Caulier","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0950-3579(05)80292-4","article-title":"Drug related lupus syndromes and their relationship to spontaneously occurring systemic lupus erythematosus","volume":"5","author":"Alarcon-Segovia","year":"1991","journal-title":"Ballieres Clin Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/33.8.789-a","article-title":"Sulphasalazine-induced systemic lupus erythematosus","volume":"33","author":"Mongey","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/03009749309095143","article-title":"Follow up of patients with double stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases","volume":"22","author":"Mielke","year":"1993","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.58.5.288_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/cpt1977223251","article-title":"Clinical consequences of polymorphic acetylation of basic drugs","volume":"22","author":"Drayer","year":"1977","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724436431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724436431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.58.5.288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:27:58Z","timestamp":1737264478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724436431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["S0003496724436431"],"URL":"https:\/\/doi.org\/10.1136\/ard.58.5.288","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1999,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.58.5.288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}